SCHEMBL5079941

SCHEMBL5079941

CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)nc1)C1CCN(C(=O)CCc2ccc(F)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.42
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ME2 P23368 1/20 0.40
ME1 P48163 1/20 0.40
ME3 Q16798 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40
KCNH2 Q12809 2/20 0.40
HTR2C P28335 1/20 0.40
MCHR1 Q99705 1/20 0.40
MAPT P10636 2/20 0.39
CCR5 P51681 3/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38
MC4R P32245 1/20 0.37
MLNR O43193 1/20 0.37
GPR183 P32249 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5079900 0.95 GPR119 (0.41) GPR119ALDH1A1SMN1; SMN2KMT2ALMNA
SCHEMBL5082932 0.88 GPR119 (0.47) GPR119KMT2AKCNH2HTR2CMCHR1
SCHEMBL3978700 0.86 GPR119 (0.47) GPR119KCNH2HTR2CMCHR1
SCHEMBL3984054 0.85 GPR119 (0.48) GPR119KCNH2
SCHEMBL5079985 0.84 GPR119 (0.45) GPR119ALDH1A1KMT2AKCNH2GPR183
SCHEMBL5082860 0.84 GPR119 (0.49) GPR119KCNH2
SCHEMBL5085875 0.83 CACNA1B (0.44) GPR119SMN1; SMN2KCNH2HTR2CMCHR1
SCHEMBL5083471 0.83 CACNA1B (0.44) GPR119KCNH2HTR2CMCHR1CCR5
SCHEMBL5082124 0.83 GPR119 (0.44) GPR119ALDH1A1SMN1; SMN2KMT2ALMNA
SCHEMBL3979396 0.82 GPR119 (0.50) GPR119KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US claimed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
WO-2008025798-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (PUBL) (SE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103123-A1 New compounds GPR119, GPR139, GPR180 GPR119 1/4885ALDH1A1 1431/4885SMN1; SMN2 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.